We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Semaglutide and cardiovascular outcomes by baseline HbA<sub>1c</sub> in diabetes: the SUSTAIN 6 and PIONEER 6 trials.
- Authors
Mellbin, Linda G; Bhatt, Deepak L; David, Jens-Peter; Ekström, Kathrine; Petrie, Mark C; Rasmussen, Søren; Vilsbøll, Tina
- Abstract
This article presents a post hoc analysis of two clinical trials, SUSTAIN 6 and PIONEER 6, which examined the effects of semaglutide on major adverse cardiovascular events (MACE) in individuals with type 2 diabetes. The analysis aimed to determine the impact of semaglutide compared to a placebo based on baseline glycated hemoglobin (HbA1c) levels. The findings indicate that semaglutide reduced the risk of MACE, including cardiovascular death, non-fatal myocardial infarction, and non-fatal stroke, across various baseline HbA1c values. The study was conducted ethically and with participant consent. The article also mentions that semaglutide effectively reduces HbA1c and body weight compared to a placebo, regardless of baseline HbA1c levels. The analysis suggests that semaglutide can be used to reduce MACE in individuals with type 2 diabetes, regardless of their HbA1c values, aligning with current guidelines. The study was funded by Novo Nordisk.
- Subjects
SEMAGLUTIDE; WEIGHT loss; MAJOR adverse cardiovascular events; DIABETES; GLUCAGON-like peptide-1 receptor
- Publication
European Heart Journal, 2024, Vol 45, Issue 15, p1371
- ISSN
0195-668X
- Publication type
Abstract
- DOI
10.1093/eurheartj/ehae028